Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 6/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | PLG | P00747 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21973621 | 0.90 | ACSS2 (0.42) | ACSS2PLGMAPTPCSK9 | |
| SCHEMBL21973167 | 0.90 | ACSS2 (0.38) | ACSS2DPP4NPC1RAB9ADPP8 | |
| SCHEMBL21973156 | 0.90 | ACSS2 (0.38) | ACSS2DPP4NPC1RAB9ADPP8 | |
| Hydrochloric Acid SCHEMBL20495118 | 0.90 | ACSS2 (0.37) | ACSS2DPP4NPC1RAB9ADPP8 | |
| Hydrochloric Acid SCHEMBL20494957 | 0.90 | ACSS2 (0.37) | ACSS2DPP4NPC1RAB9ADPP8 | |
| Hydrochloric Acid SCHEMBL20494956 | 0.90 | ACSS2 (0.37) | ACSS2DPP4NPC1RAB9ADPP8 | |
| SCHEMBL21973346 | 0.85 | PPARG (0.36) | — | |
| Hydrochloric Acid SCHEMBL20495565 | 0.84 | PPARG (0.36) | — | |
| Hydrochloric Acid SCHEMBL20495564 | 0.83 | PPARG (0.35) | MAPT | |
| SCHEMBL21973357 | 0.83 | ASAH1 (0.38) | ACSS2PCSK9NPC1RAB9AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180459-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200140393-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180459-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | ACSS2 1103/4885DPP4 1785/4885PLG 3254/4885 |
| US-20200140393-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | ACSS2 1103/4885DPP4 1785/4885PLG 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.